Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ( FY 2021 ), and an outlook statement. UPDATE ON TRADING · Robust financial performance: FY 2021 unaudited revenues of at least £9.0 million (FY 2020: £2.1 million audited). · Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the £4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ( Excalibur ). · Cash and cash equivalents were £23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: £31.7 million au